Answers are grounded in this paper and cite their sources.
Systematic review explores cefotaxime's pharmacokinetics and pharmacodynamics, suggesting guidance for dosage in renal failure patients.
) of about 5.6% was observed when cefotaxime is co-administered with tazobactam. Therefore, cefotaxime depicts time-dependent killing above the minimum inhibitory concentration (MIC < 2 ug/ml), this property makes it suitable for managing infections caused by susceptible pathogens.4. This review compiles all the relevant PK and PD parameters of cefotaxime in healthy subjects. These data may assist health practitioners in adjusting the cefotaxime dose among renal failure patients to avoid toxicity.
No takes yet. Share an insight, caveat, or question.
Zubaır et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: